Peter J Houghton Selected Research

Peter J Houghton Research Topics

Disease

183	Neoplasms (Cancer) 02/2022 - 07/2002
34	Rhabdomyosarcoma 01/2022 - 04/2002
28	Ewing Sarcoma (Sarcoma, Ewing) 02/2022 - 08/2007
26	Neuroblastoma 01/2020 - 09/2002
24	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 02/2006
22	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 10/2005
22	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 04/2008
19	Leukemia 12/2019 - 08/2007
11	Wilms Tumor (Wilm's Tumor) 01/2021 - 12/2003
10	Hypoxia (Hypoxemia) 01/2022 - 12/2004
10	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2002
9	Rhabdoid Tumor (Rhabdoid Tumors) 01/2021 - 05/2008
7	Glioblastoma (Glioblastoma Multiforme) 10/2015 - 06/2008
7	Alzheimer Disease (Alzheimer's Disease) 01/2012 - 03/2004
6	Glioma (Gliomas) 01/2022 - 07/2002
6	Alveolar Rhabdomyosarcoma 01/2019 - 03/2008
5	Medulloblastoma 02/2015 - 08/2004
5	Breast Neoplasms (Breast Cancer) 10/2009 - 12/2003
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 08/2009
4	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2006
4	Cognitive Dysfunction 01/2016 - 01/2003
4	Astrocytoma (Pilocytic Astrocytoma) 10/2015 - 01/2006
4	Diarrhea 08/2012 - 07/2002
3	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 02/2008
3	Thrombocytopenia (Thrombopenia) 12/2019 - 04/2015
3	Genetic Translocation (Chromosomal Translocation) 11/2017 - 11/2014
3	Lymphoma (Lymphomas) 07/2013 - 03/2006
3	Disease Progression 01/2012 - 06/2005
3	Carcinoma (Carcinomatosis) 06/2008 - 04/2002
2	Drug-Related Side Effects and Adverse Reactions 12/2019 - 08/2009
2	Embryonal Rhabdomyosarcoma 01/2019 - 07/2007

Drug/Important Bio-Agent (IBA)

45	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 01/2021 - 12/2007
33	Pharmaceutical PreparationsIBA 12/2021 - 09/2002
18	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 07/2002
17	Sirolimus (Rapamycin)FDA Link 01/2022 - 04/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2003
13	Mechanistic Target of Rapamycin Complex 1IBA 01/2022 - 02/2008
10	Cytotoxins (Cytolysins)IBA 12/2021 - 08/2007
10	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 08/2007
9	DNA (Deoxyribonucleic Acid)IBA 02/2022 - 09/2002
9	TOR Serine-Threonine KinasesIBA 01/2018 - 04/2002
9	Topotecan (Hycamtin)FDA LinkGeneric 11/2013 - 02/2003
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2010
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 05/2007
7	Temozolomide (Temodar)FDA LinkGeneric 02/2022 - 09/2002
7	LigandsIBA 11/2020 - 10/2009
7	Phosphotransferases (Kinase)IBA 01/2020 - 02/2008
6	ProdrugsIBA 01/2021 - 09/2002
6	EnzymesIBA 02/2018 - 07/2002
6	Cisplatin (Platino)FDA LinkGeneric 02/2018 - 05/2008
5	RNA (Ribonucleic Acid)IBA 02/2022 - 10/2014
5	Messenger RNA (mRNA)IBA 01/2022 - 02/2012
5	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 04/2013
5	EWS-FLI fusion proteinIBA 01/2021 - 03/2008
5	CamptothecinIBA 01/2020 - 12/2003
5	Antineoplastic Agents (Antineoplastics)IBA 12/2019 - 05/2003
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 09/2002
4	talazoparibIBA 02/2022 - 01/2015
4	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2022 - 03/2012
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2013
4	Small Interfering RNA (siRNA)IBA 01/2020 - 09/2008
4	navitoclaxIBA 12/2019 - 06/2008
4	Histone Deacetylase InhibitorsIBA 01/2019 - 01/2006
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016 - 12/2004
4	AntibodiesIBA 12/2015 - 03/2012
4	cixutumumabIBA 12/2015 - 07/2010
4	temsirolimus FDA Link 04/2015 - 08/2003
4	Insulin-Like Growth Factor I (IGF-1)IBA 06/2013 - 01/2003
4	Cholinergic Agents (Cholinergics)IBA 10/2008 - 01/2003
4	Eukaryotic Initiation Factor-4EIBA 09/2008 - 04/2002
3	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 08/2009
3	Biological ProductsIBA 12/2019 - 08/2010
3	MLN 8237IBA 01/2019 - 07/2010
3	Transcription Factors (Transcription Factor)IBA 11/2017 - 01/2014
3	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 06/2017 - 02/2012
3	Taxoids (Taxanes)IBA 11/2015 - 10/2005
3	Antimitotic AgentsIBA 07/2015 - 10/2005
3	Insulin-Like PeptidesIBA 02/2015 - 06/2008
3	Angiogenesis InhibitorsIBA 11/2014 - 09/2012
3	Insulin (Novolin)FDA Link 06/2013 - 06/2006
3	Gefitinib (Iressa)FDA Link 08/2012 - 10/2004
3	Somatomedin Receptors (Somatomedin Receptor)IBA 05/2012 - 10/2009
3	FlavonoidsIBA 01/2012 - 03/2007
3	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2011 - 01/2003
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 05/2010 - 09/2002
3	Everolimus FDA Link 03/2010 - 08/2003
3	Acetylcholine (Acetylcholine Chloride)FDA Link 04/2007 - 11/2004
3	AcetylcholinesteraseIBA 04/2007 - 03/2004
2	Alkylating AgentsIBA 02/2022 - 09/2008
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022 - 09/2021
2	trametinibIBA 01/2022 - 01/2022
2	Histones (Histone)IBA 11/2021 - 01/2006
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 02/2015
2	ChromatinIBA 01/2021 - 01/2018
2	tazemetostatIBA 01/2021 - 01/2017
2	CytokinesIBA 11/2020 - 01/2012
2	eribulin FDA Link 01/2020 - 08/2013

Therapy/Procedure

45	Therapeutics 02/2022 - 07/2002
11	Drug Therapy (Chemotherapy) 11/2021 - 09/2002
8	Radiotherapy 11/2021 - 02/2006